Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.

Peer-Reviewed Scientific Journal Clinical Study Validates Weight Loss Benefits

Stockhouse Editorial
1 Comment| March 25, 2022

{{labelSign}}  Favorites
{{errorMessage}}


(Image via Wellbeing Digital Sciences Inc.)


A recent clinical study published in the Journal of Nutrition highlighting a healthcare company in the artificial intelligence space supports the validity of weight loss properties behind a nutritional shake.

Wellbeing Digital Sciences Inc. (NEO: MEDI, Forum) announced this week that the study, conducted by its wholly owned subsidiary, KGK Science Inc. for The Beachbody Company (NYSE: BODY, Forum) detailed its superfood nutrition shake – Shakeology.

The purpose of the 206-person study was to determine if using Shakeology twice a day could improve weight loss and metabolic outcomes in otherwise healthy overweight and obese adults.

People from across four different Canadian and US locations took part in the study where they consumed Shakeology or a calorie-matched placebo 30 minutes before breakfast and lunch, while following a calorie restricted diet for 12 weeks. The primary outcome of the Study was weight loss that was significantly greater in the Shakeology group than in the placebo group.

The study reported that greater weight loss indicated that the benefits of Shakeology do not just come from its calories, but also from its additional ingredients including the protein, fibre, superfood, and phytonutrient blends that may contribute to the benefits that people experience with the product.

There was also an increase in the metabolic hormone, adiponectin, which is produced by adipose tissue in the body and influences how a person’s body makes, uses, and stores energy.

KGK’s President and CEO, Najla Guthrie noted in a release for investors that the economic rebound from the COVID-19 pandemic is continually delivering new clients and projects to the company.

She added that the team is pleased with the study and the results that it yielded about the Shakeology product for their client.

“We look forward to potentially working more with The Beachbody Company and other such clients in the nutrition industry that ae interested in learning more about their products, intellectual property or other topics of study. KGK has a long history as an independent contract research organization and a robust pipeline of engagements ahead ….”

Wellbeing and KGK both made news this week when they were engaged by Lophos Pharmaceuticals Inc. to evaluate a path to market for sustainably grown, peyote-derived natural health products (NHPs).

A Canadian psychedelic research company focused on cultivation and drug development, Lophos’ founder and CEO, Claire Stawnyczy said in a media release on this news that her company is currently exploring the potential benefits of a peyote-derived natural health product with the support of KGK Science.

“There are challenges to growing peyote, and the thirteen-year-long natural regrowth cycle is a major threat to the endangered plant. At Lophos, we are researching accelerated, responsible cultivation techniques for reducing the long growth cycle. The goal is to provide our partners with therapeutic peyote derivatives, grown in a sustainable manner that are beneficial to the plant itself, and respectful integrations of traditional medicinal plants.”

Peyote has legal status in Canada, but the drug derived from the plant, mescaline, remains a Schedule 3 controlled substance.

Potential paths to market will be evaluated based on the safety and sanitary requirements, with a focus on NHPs, quality specifications for peyote-derived inputs, as well as permissible label claims for packaging and sales, are on the docket.


New to investing in healthcare? Check out Stockhouse tips on some of our Top Healthcare Stocks.

For more of the latest info on healthcare stocks, check out the Healthcare Trending News hub on Stockhouse.




{{labelSign}}  Favorites
{{errorMessage}}

Comments

No comments yet. Be first to comment!

Leave a Comment

You must be logged in to be able to post a comment.

Get the latest news and updates from Stockhouse on social media

Follow STOCKHOUSE Today